These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2005-005406-24 Phase III multicentric IIL study, three randomized arms (R-CVP vs R-CHOP vs R-FM),for treatment of patients with stage II-IV follicular lymphoma Studio I.I.L. di fase III, multicentrico, randomi... bad-data
Not reported 2009-012337-29 Brief induction chemoimmunotherapy with Rituximab + Bendamustine + Mitoxantrone followed by Rituximab in elderly patients with advanced stage previously untreated follicular lymphoma Chemioimmunote... 2015-01-26 due-trials
Completed, but no date 2010-019248-37 A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular Non-Hodgkin’s Lymphoma Studio di fase II con Ribomustin in combinazio... bad-data
Completed, but no date, and reported results 2011-000175-13 A phase II study of oral Panobinostat in adult patients with relapsed/refractory diffuse large B-cell lymphoma after high-dose chemotherapy with autologous stem cell transfusion (ASCT) or in adult pa... bad-data
Ongoing 2011-001421-24 Rituximab plus Bendamustine as front line treatment in frail elderly (≥70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linf... not-yet-due
Not reported 2011-003191-36 Dose-dense ABVD as first line therapy in early stage unfavorable Hodgkin’s Lymphoma: a phase II, prospective, multi-center study Studio prospettico, multicentrico, di fase II non randomizzato per v... 2017-04-29 due-trials
Ongoing 2011-003769-14 R-CHOP-14 or R-CHOP-21 & consolidation PET–oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients with low risk profile according to age-adjusted IPI (0 with bulky or 1) St... not-yet-due
Completed, but no date, and reported results 2011-005461-21 BENDAMUSTINE, LENALIDOMIDE AND RITUXIMAB (R2-B)COMBINATION AS A SECOND-LINE THERAPY FOR FIRST RELAPSED-REFRACTORY MANTLE CELL LYMPHOMAS: A PHASE II STUDY STUDIO DI FASE II SULL'USO COMBINATO DI BEN... bad-data
Completed, but no date, and reported results 2011-005739-23 Phase II study of age‐adjusted R‐BAC (Rituximab, Bendamustine, Cytarabine) as induction therapy in older patients with Mantle Cell Lymphoma (MCL) PROTOCOLLO FIL-RBAC500 RITUXIMAB-BENDAMUSTINA-CITA... bad-data
Ongoing 2012-000251-14 A PHASE III MULTICENTER, RANDOMIZED STUDY COMPARING CONSOLIDATION WITH (90)YTTRIUM-LABELED IBRITUMOMAB TIUXETAN (ZEVALIN®) RADIOIMMUNOTHERAPY VS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS... not-yet-due
Completed, but no date, and reported results Terminated 2012-000735-27 A phase II study of SGN-35 (brentuximab vedotin) of patients with relapsed or refractory Primary mediastinal large B-cell lymphoma (PMLBCL). Studio di fase II con SGN-35 (Brentuximab vedotin) nei p... bad-data
Completed, but no date, and reported results 2012-000924-16 Phase II randomized study with R-DHAP +/- Bortezomib as induction therapy in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose chemotherapy BEAM with autologous stem ... bad-data
Completed, but no date, and reported results 2012-001404-38 Phase IIa study on the role of Gemcitabine plus Romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. Studio di fase IIa sul ruolo di gemcitabina ... bad-data
Ongoing 2012-001676-11 "MIRO" study (Molecularly Oriented Immuno-radio-therapy): a multicenter phase II trail for the treatment on molecular basis of stage I / II Follicular Lymphoma with local radiotherapy with / without ... not-yet-due
Ongoing 2012-003170-60 A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular Ly... not-yet-due
Ongoing 2012-003392-18 A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-... not-yet-due
Ongoing 2013-003256-20 A PHASE II PROSPECTIVE STUDY OF HIGH-DOSE myeloablative therapy, WITH STEM CELL DEVICES SUPPORT IN ELDERLY PATIENTS (from 65 to 76 years) with relapsed aggressive non-Hodgkin lymphoma OR RESISTANT TO... not-yet-due
Completed, but no date, and reported results 2013-003934-33 A pilot phase II study with BRENTUXIMAB VEDOTIN as pre-ASCT induction therapy in relapsed/refractory Hodgkin’s lymphoma patients non responding to IGEV salvage treatment. Studio pilota di fase II ... bad-data
Ongoing 2013-003946-17 Phase II study on the role of brentuximab vedotin as single agent in the treatment of relapsed/refractory CD30 positive peripheral T cell lymphoma (PTCL) patients Studio di fase 2 sul ruolo di bren... not-yet-due
Completed, but no date, and reported results 2013-004014-17 Phase II study with Ga101-DHAP as induction therapy in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose chemotherapy BEAM with autologous stem cell transplantation (... bad-data
Ongoing 2013-004109-24 A phase II study of Brentuximab Vedotin (BV) in the treatment of elderly Hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease Studio di fase II con l’utilizzo di Bren... not-yet-due
Ongoing 2013-005129-22 FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN –BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA’S PATIENTS AT FIRST RELAPSE STUDIO DI FASE II CON BORTEZOMIB,... not-yet-due
Exempt 2013-005179-41 ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMAS: A PHASE I-II STUDY. ROMIDEPSINA... not-yet-due
Ongoing 2014-005382-79 A phase II study with bendamustine plus brentuximab vedotin in Hodgkin’s lymphoma and CD30 + peripheral T-cell lymphoma in first salvage setting: the BBV regimen. Studio di fase II con Bendamustina... not-yet-due
Completed, but no date, and reported results 2014-005697-10 GA101-miniCHOP regimen for the treatment of elderly unfit patients with diffuse large B-cell non-Hodgkin’s lymphoma. A phase II study of the Fondazione Italiana Linfomi (FIL). Trattamento di prima... bad-data
Ongoing 2015-003371-29 A combination of Lenalidomide and Rituximab as front line therapy for the treatment of elderly frail patients evaluated in CGA with Diffuse Large B-cells non-Hodgkin Lymphoma. A phase II study of the ... not-yet-due
Ongoing 2015-004830-81 A multicenter study to evaluate the anti-viral activity of an interferon-free treatment with ledipasvir/sofosbuvir (G1 and G4) and sofosbuvir/velpatasvir (G2 and G3) for patients with hepatitis C viru... not-yet-due
Completed, but no date, and reported results Terminated 2015-005273-20 Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse L... bad-data
Ongoing 2016-002509-21 A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant ‘dose-dense/dose-intense ABVD’ (ABVD DD-DI) with an interim PET response-ad... not-yet-due
Ongoing 2016-003703-62 A phase II study of metronomic chemotherapy in elderly non-fit patients (>65 years) with aggressive B-Cell lymphomas. Studio di fase II sull’uso della chemioterapia metronomica in pazienti anziani ... not-yet-due
Ongoing 2017-004628-31 Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Rituximab, bendamustina e citarabina seguiti da venetoclax (V-RB... not-yet-due
Ongoing 2017-004630-29 A phase II, open label, multicenter trial of Venetoclax (ABT-199/GDC-0199) as single agent in patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PTCL-... not-yet-due
Ongoing 2017-005137-23 Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (A... not-yet-due
Ongoing 2018-000540-25 Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D) for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas: a phase II study Carfilzomib (K) in combinazione con Lenalido... not-yet-due
Ongoing 2018-001229-18 Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study. Idelalisib (I) in combinazi... not-yet-due
Ongoing 2018-002644-91 A phase II, open label, multicenter trial of Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in patients with relapsed/refractory CD38 positive peripheral T-cell lymph... not-yet-due
Ongoing 2019-004474-26 Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL). A randomized, open label, phase III stud... not-yet-due
Ongoing 2019-004898-63 Copanlisib in combination with Rituximab-Bendamustine in patients with Relapsed-Refractory Diffuse Large B-cell Lymphoma: a multicentric Phase II trial Copanlisib in combinazione con Rituximab e Be... not-yet-due
Ongoing 2020-000409-94 An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients with Relapsed or Refractory Plasmablastic lymphoma (DALYA trial... not-yet-due
Exempt 2020-002927-13 A phase I/II b (randomized controlled) study of atezolizumab combined to BEGEV regimen as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate to autologous ste... not-yet-due
Ongoing 2020-003277-22 Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymphoma. A randomized, open label, phase III study by Fondazione... not-yet-due
Ongoing 2021-000715-23 Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (... not-yet-due